IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

News

  • Two projects involving the IMIM selected in the Spanish Innovation Agency's Challenge-Collaboration call

    30/06/2020

    The successful projects are "Obtaining antioxidant active substances from the carob pod and validating their therapeutic potential", which involves the company Euronutra, the IBIMA (Malaga Biomedical Research Institute), the IMIM (Hospital del Mar Medical Research Institute), and the CRG (Centre for Genomic Regulation); and the project "Development of a new therapy for Fragile X syndrome", in which the company Connecta Therapeutics, the IMIM, and the CRG are participating.

    The Spanish Innovation Agency call for these grants is part of the State Plan for Scientific and Technical Research and Innovation 2017-2020. The goal is to finance cooperative projects between companies and research bodies in order to carry out joint R&D projects that are close to the market and that, due to their subject matter, are aligned with the priorities established in the challenges of the State R&D Programme Oriented to the Challenges of Society.  This year's call has a budget of 260 million euros and one of the requirements is that the coordinator applying for the grant must be a company.

    Read more sobre "Two projects involving the IMIM selected in the Spanish Innovation Agency's Challenge-Collaboration call"

  • Chemotargets one of the top-20 Spanish biotech companies to watch according to the technology magazine of the Financial Times

    29/06/2020

    This month Sifted, the technology magazine of the Financial Times, has contacted various experts in the technology industry and in analyzing data on investments, has concluded that the Spanish entrepreneurial ecosystem has high quality healthtech startups, ranging from drug discovery to novel virtual reality therapies. In its latest edition, Sifted has published a list of the top healthcare start-ups in Spain, including Chemotargets, the IMIM's spin-off founded in 2006 by Dr. Jordi Mestres, coordinator of the Systems Pharmacology research group at IMIM.

    Chemotargets is a company that offers state-of-the-art methodologies with predictive capabilities that allow the pharmaceutical and biotechnology industry to accelerate the design and optimization of drug candidates and improve cost efficiency and safety. Its CLARITY® platform covers the entire field of drug discovery and development, from the de novo design of molecules for new targets to pharmacovigilance in the drug market stage.

    Read more sobre "Chemotargets one of the top-20 Spanish biotech companies to watch according to the technology magazine of the Financial Times"

  • Transfer opportunities and service offers
  • Scientific publications
  • Research projects
  • Grants and job bank
  • Clinical Research Unit
  • Info Recerca

Subscribe to our newsletter

Notice: Undefined variable: textprivacitat in /webs/test.imim.cat/en_index.html on line 672

Institut Hospital del Mar d'Investigacions Mèdiques

Dr. Aiguader, 88, 08003 Barcelona
See location on Google Maps
Phone: 93 316 04 00 · Fax: 93 316 04 10